Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CG | P48736 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 8/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 7/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.39 |
| ▸ | USP2 | O75604 | 4/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 9/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30290978 | 1.00 | PIK3CG (0.41) | PIK3CGCYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3292267 | 0.83 | PIK3CG (0.47) | PIK3CGCYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21657921 | 0.81 | PIK3CG (0.36) | PIK3CGCYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21657798 | 0.81 | PIK3CG (0.36) | PIK3CGCYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL1378685 | 0.80 | PIK3CG (0.46) | PIK3CGCYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL30792962 | 0.79 | PIK3CG (0.35) | PIK3CGCYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2629407 | 0.76 | PIK3CG (0.37) | PIK3CGCYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL30211632 | 0.76 | PIK3CG (0.37) | PIK3CGCYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2629406 | 0.76 | PIK3CG (0.37) | PIK3CGCYP2C9CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL30792945 | 0.75 | CYP1A2 (0.33) | PIK3CGCYP2C9CYP1A2CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4146222-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | Amgen Inc. (US) | 2023-03-15 | — | — | EP | claimed |
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | VIGIL NEUROSCIENCE, INC. | 2024-06-06 | — | — | US | disclosed |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2024-02-27 | — | — | US | disclosed |
| CN-117597333-A | Heterocyclic compounds as receptor 2-triggering agonists expressed on myeloid cells and methods of use | 维吉尔神经科学股份有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | AMGEN INC. | 2023-09-21 | — | — | US | disclosed |
| US-20230192695-A1 | THERMALLY ASSISTED DELAYED FLUORESCENT MATERIALS WITH TRIAD-TYPE MATERIALS | UNIV ARIZONA STATE (US) | 2023-06-22 | — | — | US | disclosed |
| US-20230192695-A1 | THERMALLY ASSISTED DELAYED FLUORESCENT MATERIALS WITH TRIAD-TYPE MATERIALS | UNIV ARIZONA STATE (US) | 2023-06-22 | — | — | US | disclosed |
| US-11608344-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | AMGEN INC. (US) | 2023-03-21 | — | — | US | disclosed |
| US-4680347-A | Thermosettable polystyrylpyrazine polymers terminated with ethylenically unsaturated groups and cured products therefrom | THE DOW CHEMICAL COMPANY (US) | 1987-07-14 | — | — | US | disclosed |
| US-4676834-A | Novel compositions prepared from methyl substituted nitrogen-containing aromatic heterocyclic compounds and an aldehyde or ketone | THE DOW CHEMICAL COMPANY (US) | 1987-06-30 | — | — | US | disclosed |
| US-4668766-A | Preparation of thermosettable polymer or prepolymer from heterocyclic material containing nitrogen atoms, carboxylic acid mono- or dianhydride and a polymerizable material with ethylenically unsaturated group | THE DOW CHEMICAL COMPANY (US) | 1987-05-26 | — | — | US | disclosed |
| EP-0202244-A4 | CURED PRODUCTS FROM THERMOSETTABLE POLYMERS OR PREPOLYMERS PREPARED FROM POLYMETHYLATED PYRAZINES AND AROMATIC POLYALDEHYDES. | DOW CHEMICAL CO (US) | 1987-04-28 | — | — | EP | disclosed |
| US-4654414-A | Thermosettable polymer or prepolymer prepared from heterocyclic material having alkyl substituent, mono- or dianhydride, ethylenically unsaturated material and a hydroxide, carbonate or bicarbonate of a metal of groups I-A or II-A | THE DOW CHEMICAL COMPANY (US) | 1987-03-31 | — | — | US | disclosed |
| US-4629770-A | Thermosettable polystyrylpyrazine polymers terminated with ethylenically unsaturated groups and cured products therefrom | THE DOW CHEMICAL COMPANY (US) | 1986-12-16 | — | — | US | disclosed |
| EP-0202244-A1 | CURED PRODUCTS FROM THERMOSETTABLE POLYMERS OR PREPOLYMERS PREPARED FROM POLYMETHYLATED PYRAZINES AND AROMATIC POLYALDEHYDES. | DOW CHEMICAL CO (US) | 1986-11-26 | — | — | EP | disclosed |
| US-4613663-A | Thermoplastic and thermosettable products prepared by reacting nitrogen-containing heterocyclic compounds with aromatic aldehydes | THE DOW CHEMICAL COMPANY (US) | 1986-09-23 | — | — | US | disclosed |
| WO-1986002932-A1 | THERMOSETTABLE POLYMERS OR PREPOLYMERS PREPARED FROM POLYMETHYLATED PYRAZINES AND AROMATIC POLYALDEHYDES AND CURED PRODUCTS THEREFROM | THE DOW CHEMICAL COMPANY (US) | 1986-05-22 | — | — | WO | disclosed |
| US-4543388-A | Thermosettable polymers or prepolymers prepared from polymethylated pyrazines and aromatic polyaldehydes and cured products therefrom | THE DOW CHEMICAL COMPANY (US) | 1985-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428425-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | PIK3CG 3430/4885CYP2C9 1526/4885CYP1A2 417/4885 |
| US-20230192695-A1 | THERMALLY ASSISTED DELAYED FLUORESCENT MATERIALS WITH TRIAD-TYPE MATERIALS | TTPA, TTC14, AAAS | PIK3CG 2845/4885CYP2C9 4190/4885CYP1A2 4307/4885 |
| US-20240182477-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | PIK3CG 3430/4885CYP2C9 1526/4885CYP1A2 417/4885 |
| US-11912711-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | PIK3CG 3430/4885CYP2C9 1526/4885CYP1A2 417/4885 |
| US-11608344-B2 | Heterocyclic compounds as triggering receptor expressed on myeloid cells 2 agonists and methods of use | MSR1, FPR2, CD14 | PIK3CG 3430/4885CYP2C9 1526/4885CYP1A2 417/4885 |
| US-20230295169-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | PIK3CG 3430/4885CYP2C9 1526/4885CYP1A2 417/4885 |
| US-20230295170-A1 | HETEROCYCLIC COMPOUNDS AS TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2 AGONISTS AND METHODS OF USE | MSR1, FPR2, CD14 | PIK3CG 3430/4885CYP2C9 1526/4885CYP1A2 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.